Edinburgh Pathology

Professor C Simon Herrington

Professor of Molecular Cancer Pathology

+44 (0)131 651 8624


Cancer Research UK Edinburgh Centre

University of Edinburgh

Western General Hospital

Crewe Road South

Edinburgh, EH4 2XR


PA Jan Irvine

Tel +44 (0)131 651 8690

Email Jan.Irvine@ed.ac.uk

Current Research

My main research interest is pathological aspects of ovarian tumours, as part of the Nicola Murray Centre for Ovarian Cancer Research (Prof Charlie Gourley), with current projects including the molecular investigation of high-grade serous, low grade serous, endometrioid and clear cell ovarian carcinomas. I am Editor in Chief of The Journal of Pathology: Clinical Research. My research interests are aligned with my clinical practice in gynaecological pathology as a Consultant Pathologist with NHS Lothian.

Group Members

Name Role Telephone Email
Emily Southworth PhD Student   Email Emily Southworth

Web Links

Full publication list

The Journal of Pathology: Clinical Research Website


  • Prof Charlie Gourley, Oncology, University of Edinburgh
  • Prof Mark Arends, Pathology, University of Edinburgh

Selected Publications

Hollis RL, Meynert AM, Michie CO, Rye T, Churchman M, Croy I, McCluggage WG, Williams ARW, Dougherty B, Matakidou A, March R, Barrett JC, Roxburgh P, Semple CA, Kennedy R, Herrington CS, Gourley C, "Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification", Clin Cancer Res. 2022; 283546-3556. doi: 10.1158/1078-0432.CCR-22-0368. PMID: 35696721.

Hollis RL, Croy I, Churchman M, Bartos C, Rye T, Gourley C, Herrington CS, "Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high grade serous carcinoma", Br J Cancer. 2022; 127: 1034–1042. doi: 10.1038/s41416-022-01874-8

Sanderson PA, Esnal-Zufiaurre A, Arends MA, Herrington CS, Collins F, Williams ARW, Saunders PTK, "Improving the diagnosis of endometrial hyperplasia using computerized analysis and immunohistochemical biomarkers", Front Reprod Health. 2022; 4: 896170. doi: 10.3389/frph.2022.896170 . PMID: 36303676.

Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, Millan D, Coleman RL, Moore KN, Banerjee S, Connolly K, Alvarez Secord A, O’Malley DM, Dorigo O, Gaillard S, Gabra H, Slomovitz B, Hanjani P, Farley J, Churchman M, Ewing A, Hollis RL, Herrington CS, Huang HQ, Wenxel L, Gourley C, "Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): a randomized, open-label phase 2/3 trial", Lancet. 2022; 399: 541-553. doi: 10.1016/S0140-6736(21)02175-9. PMID: 35123694.

Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Raza Mirza M, Kurtz JE, Okamoto A, Moore K, Kridelka F, McNeish I, Reuss A, Votan B, du Bois A, Mahner S, Ray-Coquard I, Kohn EC, Berek JS, Tan DSP, Colombo N, Zang R, Concin N, O’Donnell D, Rauh-Hain A, Herrington CS, Marth C, Poveda A, Fujiwara K, Stuart GCE, Oza A, Bookman MA, on behalf of the participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research. "Gynecologic Cancer InterGroup consensus recommendations on clinical research in ovarian cancer". Lancet Oncol. 2022; 23: e374-384. doi: 10.1016/S1470-2045(22)00139-5. PMID: 35901833.

Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Rossi PG, Kupets R, Smith R, Arrossi S, Bendahhou K, Canfell, K, Chirenje M, Chung MH, del Pinto M, de Sanjose S, Elfstrom M, Franco E, Hamashima C, Hamers F, Herrington CS, Murillo R, Sangrajrang S, Sankaranarayanan R, Saraiya M, Schiffman M, Zhao F, Arbyn M, Prendiville W, Indave BI, Mosquera Metcalfe I, Lauby-Secretan B, "The IARC perspective on cervical cancer screening". N Engl J Med. 2021; 385: 1908-1918. doi: 10.1056/NEJMsr2030640. PMID: 34758259.

Hollis R, Stillie LJ, Hopkins S, Bartos C, Churchman M, Rye T, Nussey F, Fegan S, Nirsimloo R, Inman G, Herrington CS, Gourley C, "Clinicopathological determinants of recurrence risk and survival in mucinous ovarian carcinoma". Cancers (Basel). 2021; 13: 5839. doi: 10.3390/cancers13225839. PMID: 34830992.

Heong V, Miwa M, Tan TZ, Ye J, Lim D, Herrington CS, Iida Y, Yano M, Yasuda M, Ngoi NYL, Okamoto A, Gourley C, Hasegawa K, Tan DS, Huang RY, "A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma". J Pathol. 2021; 255: 285-295. doi: 10.1002/path.5769. PMID: 34322886.

Hollis R, Thomson JP, Stanley B, Churchman M, Meynert AM, Rye T, Bartos C, Iida Y, Croy I, Mackean M, Nussey F, Okamoto A, Semple CA, Gourley C, Herrington CS, "Integrated molecular characterization of endometrioid ovarian carcinoma identifies opportunities for stratification", npj Precis Oncol. 2021; 5: 47. doi: 10.1038/s41698-021-00187-y. PMID: 34079052.

Ewing A, Meynert A, Churchman M, Grimes G, Hollis R, Herrington CS, Rye T, Bartos C, Croy I, Ferguson M, Lennie M, McGoldrick T, McPhail N, Siddiqui N, Dowson S, Glasspool R, Mackean M, Nussey F, McDade B, McMahon L, Matakidou A, Dougherty B, March R, Barrett JC, McNeish I, Biankin A, Roxburgh P, Gourley C, Semple C, "Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma", Clin Cancer Res. 2021; 27: 3201-3214. doi: 10.1158/1078-0432.CCR-20-4068. PMID: 33741650.

Hollis R, Thomson JP, Stanley B, Churchman M, Meynert AM, Rye T, Bartos C, Iida Y, Croy I, Mackean M, Nussey F, Okamoto A, Semple CA, Gourley C, Herrington CS, "Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome", Nat Commun. 2020; 11: 4995.  doi: 10.1038/s41467-020-18819-5. PMID: 33020491.

Irodi A, Rye T, Herbert K, Churchman M, Bartos C, Mackean M, Nussey F, Herrington CS, Gourley C, Hollis RL, "Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data", BJOG. 2020; 127: 1409-1420. doi: 10.1111/1471-0528.16264. PMID: 32285600.

Hollis RL, Stanley B, Iida Y, Thomson J, Churchman M, Rye T, Mackean M, Nussey F, Gourley C, Herrington CS, "Hormone receptor expression patterns define clinically meaningful subgroups of ovarian endometrioid carcinoma", Gynecol Oncol. 2019; 155: 318-323. doi: 10.1016/j.ygyno.2019.09.001. PMID: 31495455.

Hollis RL, Carmichael J, Meynert AM, Churchman M, Hallas-Potts A, Rye T, Mackean M, Nussey F, Semple CA, Herrington CS, Gourley C, "Clinical and molecular characterisation of ovarian carcinoma displaying isolated lymph node relapse", Am J Obstet Gynecol. 2019; 221: 245.e1-245.e15. doi: 10.1016/j.ajog.2019.04.035. PMID: 31055034. 

Hallas-Potts A, Dawson JC, Herrington CS, "Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas", Sci Rep. 2019; 9: 5515. doi: 10.1038/s41598-019-41941-4. PMID: 30940866.